Soluble Systems, LLC

To: Honored Guests

Re: Soluble Systems, LLC, makers of TheraGauze ™, teams with The Arc of the Virginia Peninsula, Inc. as its manufacturing partner

Date: Friday, November 3, 2006 at 11:30 a.m.

Where: The Arc of the Virginia Peninsula, Inc.

2520 – 58 th Street, Hampton, Virginia 23661

Soluble Systems, LLC has teamed with The Arc of the Virginia Peninsula, Inc. to manufacture and distribute advanced wound care products, marketed as TheraGauze™. This new technology was developed in collaboration with Polymer Solutions, Inc., located in the Virginia Tech Corporate Research Center in Blacksburg, Virginia. The Arc of the Virginia Peninsula will manufacture TheraGauze at its facility in Hampton and provide jobs for people with developmental disabilities.  Established in 1953, The Arc currently serves over 1600 individuals annually in employment, community living, day, and early childhood programs. Soluble Systems, LLC is a closely held Newport News based company which holds the USPTO and Foreign Patents for the breakthrough polymer wound care technology found in TheraGauze™.

Dr. Adam Landsman, a member of the faculty at Harvard University School of Medicine and Chair of the Medical Advisory Board for Soluble Systems, LLC, has been impressed with TheraGauze ™ in his research-based practice. “TheraGauze™ is a non-adherent product which can dynamically absorb or release moisture, and causes no pain with removal.   Furthermore, other wound dressings slip and slide, particularly on the foot, where there is a lot of movement.  TheraGauze ™ adheres to the healthy areas, minimizing slippage, but does not adhere to the wound!  As a result, it can potentially reduce shear forces to the wound.  So TheraGauze ™ is non-occlusive, but controls fluid content, resists shear forces on the wound, and is pain free during dressing changes; I am unaware of any other wound care product on the market that does all of this.”

Kerry McCarter, a long-time Johnson & Johnson executive and now CEO of Soluble Systems, is equally enthusiastic. “I see tremendous market opportunities for TheraGauze ™ in multiple wound categories. We are currently running tests at Northwestern and Harvard Universities involving diabetic foot ulcers, which plague hundreds of thousands of diabetics annually, with ten to fifteen percent of these foot ulcers resulting in amputations and, all too frequently, loss of life.” McCarter states that they are also targeting TheraGauze ™ for burns, amputations and other traumatic injuries, and are expecting to begin testing soon at a number of military hospitals.

“This is really the ultimate win-win situation,” states Kasia Grzelkowski , President /CEO of The Arc of the Virginia Peninsula, “We are able to create meaningful employment for people with developmental disabilities, while making a product that will significantly improve the treatment of a variety of wounds and injuries.”